Form 4: ResMed CFO Sandercock Earns 2,710 Performance Shares

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, acquired 2,710 shares of common stock after performance metrics for restricted stock units were met.

Summary

• Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), acquired 2,710 shares of ResMed Common Stock.
• The acquisition resulted from the earning of performance-based restricted stock units (RSUs) that were granted on November 16, 2022.
• The shares were earned on November 20, 2025, after the compensation and leadership development committee certified that the associated performance metrics were met.
• Following this transaction, Brett Sandercock beneficially owns 88,495 shares of ResMed Common Stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The sentiment is positive as a key executive successfully met performance targets, leading to increased stock ownership and better alignment with shareholder interests. This is a routine, positive event for corporate governance and executive motivation.

Positives

• The earning of performance-based restricted stock units indicates that the company's compensation and leadership development committee certified the achievement of specific performance metrics.
• Increased direct ownership by the Chief Financial Officer, Brett Sandercock, enhances alignment between management's interests and shareholder value.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the completion of a past performance period for executive compensation.

Management Comments

• Brett Sandercock, Chief Financial Officer, signed the filing on November 21, 2025.

Industry Context

This transaction represents a routine executive compensation event, where performance-based restricted stock units vest upon the achievement of pre-defined company performance targets. Such compensation structures are standard practice in publicly traded companies, particularly in the medical device and healthcare technology sector where ResMed operates, aiming to align executive incentives with long-term shareholder value creation.

Comparison to Industry Standards

• Executive compensation structures involving performance-based restricted stock units are a common practice across industries, aligning executive incentives with company performance and shareholder value creation.
• This specific vesting event is consistent with typical long-term incentive plans observed in comparable companies within the medical technology sector, where executives are rewarded for achieving strategic and financial milestones.

Stakeholder Impact

• Shareholders: Increased alignment of the CFO's interests with shareholder value through direct stock ownership.
• Employees: May signal successful company performance, potentially boosting morale and confidence in leadership.

Key Dates

Recommendation

The vesting of performance-based restricted stock units for a key executive like the CFO is a positive indicator of management's achievement of set performance targets and increased alignment with shareholder interests. However, this routine compensation event alone does not provide sufficient new information to warrant a change in investment recommendation for ResMed Inc.

Keywords

ResMed, RMD, Brett Sandercock, CFO, Insider Transaction, Form 4, Restricted Stock Units, Performance Shares, Executive Compensation, Stock Ownership